
5.1.2e @rivm.nl] To: From: Sent: Wed 3/3/2021 10:13:51 AM Subject: FW: Eurosurveillance update on your manuscript MS 20-01134 Received: Wed 3/3/2021 10:13:54 AM 5.1.2e docx **PREFINAL** 5.1.2e Molecular testing Attached the latest edited version of our manuscript. Have you got any more comments? Or shall I send it back to them? All the best National Institute for Public Health and the Environment (RIVM) Antonie van Leeuwenhoeklaan 9 | 3720 MA Bilthoven | The Netherlands 5.1.2e 5.1.2e I http://www.rivm.nl From: 5.1.2e 5.1.2e @ecdc.europa.eu> Sent: 02 March 2021 18:27 5.1.2e To: @rivm.nl> @rivm.nl>; @ecdc.europa.eu> Subject: RE: Eurosurveillance update on your manuscript MS 20-01134 5.1.2e and 5.1.2e Sorry that I was not able to get back to you earlier. l attach a version of your manuscript with another round of edits/point for clarifications from me and 5.1.2e There are not many and they should be easy to address. After this round we may be able to prepare a final for approval. There will be minor changes to the figures 5.1.2e will handle them Meanwhile we can continue to work on the text and you can already line up the co-authors for their approval next week if possible by Wednesday so we can publish on Thursday - what do you think? Kind regards Eurosurveillance **Published by European Centre for Disease** Prevention and Control (ECDC) 5.1.2e Eurosurveillance Gustav III:s boulevard 40, 169 73 Solna, Sweden 5.1.2e Phone Phone +46 (0)8 58 60 10 00 / Fax +46 (0)8 58 60 10 01 5.1.2e @ecdc.europa.eu www.eurosurveillance.org



From: @ecdc.europa.eu> Sent: 24 February 2021 11:32 To: @rivm.nl> 5.1.2e Cc @rivm.nl> Subject: Eurosurveillance update request MS 20-01134 Dear 5.1.2e and 5.1.2e

I hope that the edited version of the manuscript I sent last week arrived well to you.

If you are working on this still, could you please provide us with an update on when you think you can send us the next version? Indeed, this will be helpful for planning from our side.

Wishing you a nice day,

Kind regards,

@ecdc.europa.eu> From: 5.1.5 Sent: 20 February 2021 18:10 To: @rivm.nl> Cc: @rivm.nl>

Subject: Eurosurveillance edited version of manuscript MS 20-01134

and 5.1.2e 5.1.2e

Apologies for the delay. This took a bit more time to edit than I anticipated, as it is a quite large manuscript.

Attached, you will find an edited version of your manuscript.

I kindly ask you to please go through this version to see if you are happy with the editing, and to please address the editorial comments, which can be viewed in the 'track-change' mode.

Please note that there are also comments after the main text, in the 'conflict of interest' and 'reference' sections. For the references, please do not make changes using a reference software as this will interfere with our editing software, but please indicate any change you would like to implement in the answers to the bubble comments.

If you agree with my edits, you can simply accept them, however if you make any new revisions, I kindly ask you to please keep these tracked so we can more easily see what has been done.

Overall, the comments should be quite straightforward, so we would prefer, if possible, to receive the next version of the manuscript by 9 am on Tuesday 23 February. Should you need more time however, please just inform us, so we can plan accordingly.


In the next round of editing, according to our routines, your manuscript will be checked by the Editor-in-chief, so there could be a few more comments at that stage. I will also be in touch regarding the designed figures.

Looking forward to further corresponding concerning the manuscript, I kindly ask you to please remain contactable this week as, all being well, we will attempt to finalise everything as soon as possible. I also remind below on our procedures for regular manuscripts, in case you wish to prepare your co-authors.

Kind regards,

Procedures for regular manuscripts: Once all issues regarding a given manuscript have been satisfactorily addressed subsequent to editing, the manuscript is finalised, and a final edited version of the manuscript is then sent by the editor to the corresponding author. At that final stage, we expect the corresponding author to ensure that all named authors see the final edited version, and, if all authors approve of this final edited version for publication, we kindly request the corresponding author to state in an email to us, that all named authors have seen and approve the final edited version for publication.





Friday 19 February.

Should I experience any delays however, I will send you an update about the situation around 2:30 pm tomorrow. In the meantime, I take the opportunity of this email to inform on our procedures for regular manuscripts, in case you wish to prepare co-authors.

Kind regards,

5.1.2e

Procedures for regular manuscripts: Once all issues regarding a given manuscript have been satisfactorily addressed <u>subsequent to editing</u>, the manuscript is finalised, and a <u>final edited version</u> of the manuscript is then sent by the editor to the corresponding author. At that final stage, we expect the corresponding author to ensure that <u>all named authors see the final edited version</u>, and, if all authors approve of this final edited version for publication, we kindly request the corresponding author to state in an email to us, that all named authors have seen and approve the final edited version for publication.

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en Committed to health and sustainability

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en Committed to health and sustainability

Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.